Table 3 Characteristics of responders... | American Society of Hematology

Table 3

Characteristics of responders

Patient ID	Age, y	Sex	Immunophenotype	No. of prior therapies	Refractory to immediate prior regimen	Best response	No. of cycles to best response/total no. of cycles	DOR, wk*	MRD status after induction	Went to HSCT	OS, wk*
32	20	M	B	2	No	CRp	1/1	67.3	NE	Yes	80.9
27	20	F	B	2	No	CR	1/2	109.6+	NE	Yes	113.1+
36	3	M	Unknown	3	Yes	CR	2/3	13.4	−†	No	38.6
43	7	M	Unknown	1‡	Yes	CR	1/2	38.1+	NE	Yes	40.7+
26	14	F	B	1‡	Yes	CRp	1/1	67.7+	NE	Yes	101.9+
38	6	M	B	2	Yes	CR	1/2	56.9+	NE	Yes	59.9+
46	17	M	B	2	Yes	CR	1/1	2.9	NE	No	8.1
40	12	M	B	2	Yes	CRp	1/2	50.1+	§	Yes	53.1+
48	17	M	B	2	Yes	CR	1/2	5.3	+	No	11.7
47	15	M	B	1‖	No	CRp	1/2	30.1+	¶	No	35.9+
37	14	F	B	2	No	CR	1/3	15.9	NE	Yes	22.6

Patient ID	Age, y	Sex	Immunophenotype	No. of prior therapies	Refractory to immediate prior regimen	Best response	No. of cycles to best response/total no. of cycles	DOR, wk*	MRD status after induction	Went to HSCT	OS, wk*
32	20	M	B	2	No	CRp	1/1	67.3	NE	Yes	80.9
27	20	F	B	2	No	CR	1/2	109.6+	NE	Yes	113.1+
36	3	M	Unknown	3	Yes	CR	2/3	13.4	−†	No	38.6
43	7	M	Unknown	1‡	Yes	CR	1/2	38.1+	NE	Yes	40.7+
26	14	F	B	1‡	Yes	CRp	1/1	67.7+	NE	Yes	101.9+
38	6	M	B	2	Yes	CR	1/2	56.9+	NE	Yes	59.9+
46	17	M	B	2	Yes	CR	1/1	2.9	NE	No	8.1
40	12	M	B	2	Yes	CRp	1/2	50.1+	§	Yes	53.1+
48	17	M	B	2	Yes	CR	1/2	5.3	+	No	11.7
47	15	M	B	1‖	No	CRp	1/2	30.1+	¶	No	35.9+
37	14	F	B	2	No	CR	1/3	15.9	NE	Yes	22.6

NE indicates not evaluable.

Censored at date of last known follow-up visit.

After 3 cycles.

Primary refractory.

After 1 cycle.

Duration of first remission, 206 weeks.

After 2 cycles plus censored observation.